Cargando…
Broad funding for oxaliplatin in Ontario (finally!)
Autores principales: | Jonker, D., Maroun, J., Spithoff, K. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2133092/ https://www.ncbi.nlm.nih.gov/pubmed/18080013 |
Ejemplares similares
-
Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer
por: Jonker, D., et al.
Publicado: (2006) -
Challenges in funding and developing genomic software: roots and remedies
por: Siepel, Adam
Publicado: (2019) -
The mission to ensure continued funding for excellent basic research
por: Lamond, Angus I., et al.
Publicado: (2023) -
The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOx
por: Karlsson, Jan Olof G., et al.
Publicado: (2021) -
Closing the Gaps to Timely Patient Access: Perspectives on Conditional Funding Models
por: Glennie, Judith, et al.
Publicado: (2022)